Alberto Pérez-Gómez

Dr. Alberto Pérez-Gómez

Research Institute Hospital 12 de Octubre, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
APAlberto Pérez-Gómez
Alberto Pérez-Gómez
JVJoana Vitallé
Joana Vitallé
CGCarmen Gasca-Capote
Carmen Gasca-Capote
AGAlicia Gutierrez-Valencia
Alicia Gutierrez-Valencia
MTMaría Trujillo-Rodriguez
María Trujillo-Rodriguez
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos

8 September 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
JVJoana Vitallé
Joana Vitallé
APAlberto Pérez-Gómez
Alberto Pérez-Gómez
Francisco José Ostos MarcosFrancisco José Ostos Marcos
Francisco José Ostos Marcos
CGCarmen Gasca-Capote
Carmen Gasca-Capote
MJMaría Reyes Jiménez-León
María Reyes Jiménez-León
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
The immune factors associated with impaired SARS-CoV-2 vaccine response in elderly people are mostly unknown. We studied individuals older than 60 and younger than 60 years, who had been vaccinated with SARS-CoV-2 BNT162b2 mRNA, before and after the first and second dose. Aging was associated with a lower anti–RBD IgG levels and a decreased magnitude and polyfunctionality of SARS-CoV-2–specific T cell response. The dramatic decrease in thymic function in people > 60 years, which fueled alteration in T cell homeostasis, and their lower CD161 + T cell levels were associated with decreased T cell response 2 months after vaccination. Additionally, deficient DC homing, activation, and TLR-mediated function, along with a proinflammatory functional profile in monocytes, were observed in the > 60-year-old group, which was also related to lower specific T cell response after vaccination. These findings might be relevant for the improvement of the current vaccination strategies and for the development of new vaccine prototypes.

20 February 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CGCarmen Gasca-Capote
Carmen Gasca-Capote
XLXiaodong Lian
Xiaodong Lian
CGCe Gao
Ce Gao
IRIsabelle C. Roseto
Isabelle C. Roseto
MJMaría Reyes Jiménez-León
María Reyes Jiménez-León
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
BACKGROUND: Persistent controllers (PCs) maintain antiretroviral-free HIV-1 control indefinitely over time, while transient controllers (TCs) eventually lose virological control. It is essential to characterize the quality of the HIV reservoir in terms of these phenotypes in order to identify the factors that lead to HIV progression and to open new avenues toward an HIV cure. METHODS: The characterization of HIV-1 reservoir from peripheral blood mononuclear cells was performed using next-generation sequencing techniques, such as full-length individual and matched integration site proviral sequencing (FLIP-Seq; MIP-Seq). RESULTS: PCs and TCs, before losing virological control, presented significantly lower total, intact, and defective proviruses compared with those of participants on antiretroviral therapy (ART). No differences were found in total and defective proviruses between PCs and TCs. However, intact provirus levels were lower in PCs compared with TCs; indeed the intact/defective HIV-DNA ratio was significantly higher in TCs. Clonally expanded intact proviruses were found only in PCs and located in centromeric satellite DNA or zinc-finger genes, both associated with heterochromatin features. In contrast, sampled intact proviruses were located in permissive genic euchromatic positions in TCs. CONCLUSIONS: These results suggest the need for, and can give guidance to, the design of future research to identify a distinct proviral landscape that may be associated with the persistent control of HIV-1 without ART. FUNDING: Instituto de Salud Carlos III (FI17/00186, FI19/00083, MV20/00057, PI18/01532, PI19/01127 and PI22/01796), Gilead Fellowships (GLD22/00147). NIH grants AI155171, AI116228, AI078799, HL134539, DA047034, MH134823, amfAR ARCHE and the Bill and Melinda Gates Foundation.

12 April 2022 in Clinical and Translational Medicine
Verified
Journal Article
Open access
APAlberto Pérez-Gómez
Alberto Pérez-Gómez
CGCarmen Gasca‐Capote
Carmen Gasca‐Capote
JVJoana Vitallé
Joana Vitallé
Francisco José Ostos MarcosFrancisco José Ostos Marcos
Francisco José Ostos Marcos
ASAna Serna‐Gallego
Ana Serna‐Gallego
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
SARS‐CoV‐2 specific T‐cell response has been associated with disease severity, immune memory and heterologous response to endemic coronaviruses. However, an integrative approach combining a comprehensive analysis of the quality of SARS‐CoV‐2 specific T‐cell response with antibody levels in these three scenarios is needed. In the present study, we found that, in acute infection, while mild disease was associated with high T‐cell polyfunctionality biased to IL‐2 production and inversely correlated with anti‐S IgG levels, combinations only including IFN‐γ with the absence of perforin production predominated in severe disease. Seven months after infection, both non‐hospitalised and previously hospitalised patients presented robust anti‐S IgG levels and SARS‐CoV‐2 specific T‐cell response. In addition, only previously hospitalised patients showed a T‐cell exhaustion profile. Finally, combinations including IL‐2 in response to S protein of endemic coronaviruses were the ones associated with SARS‐CoV‐2 S‐specific T‐cell response in pre‐COVID‐19 healthy donors’ samples. These results could have implications for protective immunity against SARS‐CoV‐2 and recurrent COVID‐19 and may help for the design of new prototypes and boosting vaccine strategies.

3 April 2023 in EBioMedicine
Verified
Journal Article
Open access
MJMaria R. Jimenez-Leon
Maria R. Jimenez-Leon
CGCarmen Gasca-Capote
Carmen Gasca-Capote
LTLaura Tarancon-Diez
Laura Tarancon-Diez
BDBeatriz Dominguez-Molina
Beatriz Dominguez-Molina
MLMacarena Lopez-Verdugo
Macarena Lopez-Verdugo
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and -9 and translate this sensing into Interferon-α (IFN-α) production and T-cell activation. The understanding of the mechanisms involved in pDCs stimulation may contribute to HIV-cure immunotherapeutic strategies. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations in several HIV-1 disease progression phenotypes and in non HIV-1 infected donors. pDCs, CD4 and CD8 T-cells were isolated from 450 ml of whole blood from non HIV-1 infected donors, immune responders (IR), immune non responders (INR), viremic (VIR) and elite controller (EC) participants. pDCs were stimulated overnight with AT-2, CpG-A, CpG-C and GS-9620 or no stimuli. After that, pDCs were co-cultured with autologous CD4 or CD8 T-cells and with/without HIV-1 (Gag peptide pool) or SEB (Staphylococcal Enterotoxin B). Cytokine array, gene expression and deep immunophenotyping were assayed. pDCs showed an increase of activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels after TLR stimulation in the different HIV-disease progression phenotypes. This pDC activation was prominent with CpG-C and GS-9620 and induced an increase of HIV-specific T-cell response even in VIR and INR comparable with EC. This HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production by pDC. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with the induction of a T-cell mediated antiviral response which is essential for HIV-1 eradication strategies. This work was supported by 10.13039/100005564 Gilead fellowship program, the 10.13039/501100004587 Instituto de Salud Carlos III ( 10.13039/501100008530 Fondo Europeo de Desarrollo Regional , 10.13039/501100002924 FEDER , “a way to make Europe”) and the Red Temática de Investigación Cooperativa en SIDA and by the 10.13039/501100003339 Spanish National Research Council ( 10.13039/501100003339 CSIC ).

11 January 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
HÁHortensia Álvarez-Díaz
Hortensia Álvarez-Díaz
EREzequiel Ruiz-Mateos
Ezequiel Ruiz-Mateos
PJPedro Miguel Juiz-González
Pedro Miguel Juiz-González
JVJoana Vitallé
Joana Vitallé
IVIrene Vieitez
Irene Vieitez
Josep Maria LlibreJosep Maria Llibre
Josep Maria Llibre
Intra-host evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been reported in cases with persistent coronavirus disease 2019 (COVID-19). In this study, we describe a severely immunosuppressed individual with HIV-1/SARS-CoV-2 coinfection with a long-term course of SARS-CoV-2 infection. A 28-year-old man was diagnosed with HIV-1 infection (CD4+ count: 3 cells/µL nd 563000 HIV-1 RNA copies/mL) and simultaneous Pneumocystis jirovecii pneumonia, disseminated Mycobacterium avium complex infection and SARS-CoV-2 infection. SARS-CoV-2 real-time reverse transcription polymerase chain reaction positivity from nasopharyngeal samples was prolonged for 15 weeks. SARS-CoV-2 was identified as variant Alpha (PANGO lineage B.1.1.7) with mutation S:E484K. Spike-specific T-cell response was similar to HIV-negative controls although enriched in IL-2, and showed disproportionately increased immunological exhaustion marker levels. Despite persistent SARS-CoV-2 infection, adaptive intra-host SARS-CoV-2 evolution, was not identified. Spike-specific T-cell response protected against a severe COVID-19 outcome and the increased immunological exhaustion marker levels might have favoured SARS-CoV-2 persistence.